Dec 18 (Reuters) - Krystal Biotech Inc KRYS.O:
KRYSTAL BIOTECH ANNOUNCES EARLY EVIDENCE OF MONOTHERAPY ACTIVITY IN HEAVILY PRE-TREATED PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
REPORTS 27% ORR AND 73% DCR IN NSCLC TRIAL
MAJORITY OF TREATMENT-RELATED ADVERSE EVENTS BEEN MILD TO MODERATE IN SEVERITY & TRANSIENT, WITH NO GRADE 4 OR 5 ADVERSE EVENTS OBSERVED
Source text: ID:nGNX3mDtjH
Further company coverage: KRYS.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.